Published: September 2025

Last updated: September 2025

From Data to Decisions: Leveraging Statistics to Improve Healthcare Decision-Making

Health economics is an important field not just in the UK but globally. Decision-makers can use it to prioritise resources used in healthcare systems to maximise population health whilst ensuring value for money. Since 1999, the National Institute for Health and Care Excellence (NICE) has been responsible for these decisions in the UK. There is a need to provide these decision-makers with the best possible evidence for new treatments to support well-informed decisions.

The vast majority of health economic modelling is still conducted using Markov models to capture disease progression. However, these models rely on restrictive assumptions that may not accurately capture real-world disease progression. This talk will discuss two examples from a recent publication
where regression modelling was used to improve the health economic model. The first example will cover using a multinomial logistic regression to predict the changes in haemoglobin health states over time in patients with chronic kidney disease. Traditional Markov models assume a fixed disease progression rate which fails to account for patient subgroups and time-varying rates. Regression models enable dynamic transitions based on patient characteristics like age, sex, and baseline haemoglobin levels. This leads to better modelling of disease progression and subsequent decision-making.

The second example will cover using a generalised linear mixed model (GLMM) to estimate drug doses for each haemoglobin health state whilst adjusting for subgroup characteristics. This allows for a more granular approach to cost-effectiveness analysis. Unlike Markov models, which often require simplifying assumptions to capture drug doses, a GLMM better reflects the uncertainty in the target-population.

As real-world evidence and individual patient data (IPD) become more accessible, alongside increasing computational power, statisticians must apply and share advanced modelling approaches. By doing so, we can enhance healthcare decision-making, ultimately leading to better policies and improved population health.

You may also be interested in

Peer-reviewed publication

Mitigating Bias in Health-Related Quality of Life (HRQoL) Estimation Due to Missing Data: A Simulation-Based Study Evaluating Imputation Methods

YHEC authors: Joe Moss, Neil Hansell, Erin Barker, Matthew Taylor
Publication date: August 2026
Publishers: MDPI
Journal: Health Economics & Policy

Abstract

Missing Health-Related Quality of Life (HRQoL) data in clinical studies risk propagating bias into health technology assessments (HTAs) and cost-utility analyses. Despite this, current National Institute for Health and Care...

Peer-reviewed publication

Cost-Effectiveness of Maternal RSVpreF Vaccination Compared with Newborn Nirsevimab RSV Prophylaxis or No RSV Prophylaxis in Switzerland

YHEC authors: Amy Dymond, Stuart Mealing, Charlotte Graham
Publication date: August 2026
Journal: Applied Health Economics and Health Policy

Abstract

BACKGROUND: RSVpreF is a vaccine that immunises against respiratory syncytial virus (RSV), a seasonal respiratory virus, that can lead to lower respiratory tract infections. In Switzerland, RSVpreF is indicated for...

Peer-reviewed publication

Eliciting Health State Utilities for Open Wounds in Dystrophic Epidermolysis Bullosa

YHEC authors: Damian Lewis, Adam B. Smith, Andria Joseph
Publication date: July 2026
Journal: Quality of Life Research

Abstract

PURPOSE: Qualitative accounts and studies employing disease-specific outcome measures have demonstrated that people with dystrophic epidermolysis bullosa (DEB) display impaired health-related quality of life (HRQoL) due to wound-related challenges. There...